View live charts, options flow & technicals for Neurocrine Biosciences, Inc. →
Open Dashboard
Neurocrine Biosciences, Inc. (NBIX) is a healthcare company in the drug manufacturers - specialty & generic industry with $3.37B in trailing revenue trading at a 20.2× trailing P/E — analyst consensus: strong buy.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Key Statistics
Market Cap
$14.07B
Revenue (TTM)
$3.37B
EPS (TTM)
$6.84
EPS (Fwd est.)
$11.97
Employees
2,500
Trailing P/E
20.23
Forward P/E
11.56
PEG Ratio
0.28
Price / Sales
4.17
Price / Book
3.81
EV / EBITDA
15.48
Beta (5Y)
0.38
Analyst Consensus
Consensus
Strong Buy
Analyst Price Target
+50.6% upside
Target: $208.40
Annual Revenue & Net Income
RevenueNet Income
'22
$1.49B
$150.00M
'23
$1.89B
$250.00M
'24
$2.36B
$340.00M
'25
$2.86B
$480.00M
Earnings History
Quarter
Actual EPS
Estimate
Result
Jul 2026
$2.85
$1.96
Beat (+45.4%)
May 2026
$1.94
$1.70
Beat (+14.4%)
Feb 2026
$1.88
$2.30
Miss (-18.1%)
Oct 2025
$2.17
$2.07
Beat (+4.9%)
Next Earnings Report
Neurocrine Biosciences, Inc. is next expected to report earnings on 28 Oct 2026.
Profitability
64.5%
22.2%
20.9%
Gross MarginOperating MarginNet Margin
Revenue Growth (YoY)
39.5%
Return on Equity
22.1%
Return on Assets
11.7%
Balance Sheet
Cash & Equivalents
$390.00M
Total Debt
$460.00M
Net Position
$70.00M (net debt)
Free Cash Flow (TTM)
$640.00M
Debt / Equity
12.50
Share Ownership
Institutions 102.8%
Insiders 1.1%
Institutional figure exceeds 100% due to short selling
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSI…
What is NBIX's market cap?
Neurocrine Biosciences, Inc. has a market capitalization of approximately $14.07B.
What is NBIX's P/E ratio?
Neurocrine Biosciences, Inc. trades at a trailing P/E ratio of 20.2x and a forward P/E of 11.6x, which is below the broad market average of ~25x.
How much revenue does NBIX generate?
Neurocrine Biosciences, Inc. generated $3.37B in trailing 12-month revenue.
What do analysts say about NBIX?
The analyst consensus rating for Neurocrine Biosciences, Inc. is strong buy, with a mean price target of $208.40. That implies +50.6% upside from the current price.
When does NBIX report earnings?
Neurocrine Biosciences, Inc. is next scheduled to report earnings on 28 Oct 2026.
Does NBIX pay a dividend?
Neurocrine Biosciences, Inc. does not currently pay a regular dividend.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for Neurocrine Biosciences, Inc. on Apsis Markets.
